Overview

A Study in Adults and Adolescents With Angelman Syndrome

Status:
Completed
Trial end date:
2018-08-06
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and tolerability of oral OV101 (gaboxadol) in adult and adolescent subjects with Angelman syndrome. In addition, several exploratory efficacy outcome measures will be investigated.
Phase:
Phase 2
Details
Lead Sponsor:
Ovid Therapeutics Inc.
Treatments:
Gaboxadol